While our studies employed a total of 8 (5 BD cases, 3 control) iNs and 2 (familial control and BD son) iPSCs, future studies with additional cohorts of well phenotyped BD patient and control fibroblasts reprogrammed into iNs and iPSCs are needed to determine whether miR-34a alterations in BD are common amongst all BD patients. These studies are likely to benefit from incorporation of a wider spectrum of neuropsychiatric disorder patients to understand how commonly variation in miR-34a is observed amongst patients with major depression, schizophrenia, and other disorders.
